The drug combo is the first dual checkpoint inhibitor therapy approved in Europe for first-line metastatic MSI-H or dMMR colorectal cancer.

Alyftrek is approved as a new treatment for cystic fibrosis, while the FDA expanded the label for Trikafta to include additional genetic mutations.

NEW YORK – AstraZeneca on Monday said the European Commission approved its tyrosine kinase inhibitor Tagrisso (osimertinib) as a treatment for patients with advanced, unresectable non-small cell lung ...

NEW YORK – 2024 was a banner year of "firsts" in the gene therapy space, as the US Food and Drug Administration greenlit ...

The company separately said it has started treating patients within a Phase III trial testing an ASO drug for Angelman syndrome.

R-targeted therapy PMB-CT01 for treating B-cell malignancies, including heavily pretreated follicular lymphoma.

The firms are developing the autologous CAR T-cell therapy IB-T101 as a treatment for clear cell renal cell carcinoma.

A stem cell transplant added to Rituxan did not improve survival for MRD-negative MCL patients in their first remission ...

The program, aimed at reducing how much Americans spend on prescription drugs, includes several precision medicines.

Under the terms of the agreement announced Wednesday, the Gates Foundation will invest up to $50 million to support the program's advancement into clinical testing. Tessera has said one of its goals ...

SAN ANTONIO – In a global study involving more than 5,000 women, risk-reducing surgeries significantly improved survival and ...

Researchers at the meeting reported on long-term activity of commercialized gene therapies and preliminary data on ...